Dr. B.H.G. (Barry) Rockx

Dr. Rockx received his PhD from Utrecht University in 2004 for studies on Norovirus susceptibility and antibody responses. Following his PhD, In the USA he initially worked on the evolution and pathogenesis of SARS-CoV and the development of broadly reactive therapeutic antibodies as a post-doctoral fellow at the University of North Carolina. He subsequently joined the
Laboratory of Virology at the Rocky Mountain Laboratories of the National Institutes of Health in Montana where he studied the pathogenesis and vaccine development of SARS-CoV, Influenza, Henipaviruses and Filoviruses. He continued this line of research as a tenure-track Assistant Professor at the University of Texas Medical Branch.

Last years
In 2014, Barry returned to The Netherlands as Head of the Department of Rare and Emerging Viral Infections and Response at the Center for Infectious Disease Control of the National Institute for Public Health and the Environment in Bilthoven. Since 2016, Barry is Head of the Exotic viruses workgroup in the Department of Viroscience.

Research lines
His main research lines involve studies on the tropism, pathogenesis and host responses of emerging zoonotic viruses causing hemorrhagic, respiratory and neurological diseases, including orthohantaviruses and arboviruses in a variety of in vitro and in vivo models at. He has authored over 50 peer-reviewed scientific publications, several book chapters and has supervised several post-
doctoral fellows and students. He has coordinated several NIH funded projects and contracts, and is currently Taskleader in EU Horizon 2020 and ZonMw funded projects.

Following his PhD, In the USA he initially worked on the evolution and pathogenesis of SARS-CoV and the development of broadly reactive therapeutic antibodies as a post-doctoral fellow at the University of North Carolina. He subsequently joined the Laboratory of Virology at the Rocky Mountain Laboratories of the National Institutes of Health in Montana where he studied the pathogenesis and vaccine development of SARS-CoV, Influenza, Henipaviruses and Filoviruses. He continued this line of research as a tenure-track Assistant Professor at the University of Texas Medical Branch.

Last years
In 2014, Barry returned to The Netherlands as Head of the Department of Rare and Emerging Viral Infections and Response at the Center for Infectious Disease Control of the National Institute for Public Health and the Environment in Bilthoven. Since 2016, Barry is Head of the Exotic viruses workgroup in the Department of Viroscience.

Selected publications:

• Differential virulence between Asian and African lineages of Zika virus.
  Simonin Y, van Riel D, Van de Perre P, Rockx B, Salinas S. PLoS Negl Trop Dis. 2017 Sep 21;11(9):e0005821.
• Hendra and Nipah Virus Infection in Cultured Human Olfactory Epithelial Cells.
  Borisevich V, Ozdener MH, Malik B, Rockx B.mSphere. 2017 Jun 28;2(3). pii: e00252-17.
• Contribution of Human Lung Parenchyma and Leukocyte Influx to Oxidative Stress and Immune System-Mediated Pathology following Nipah Virus Infection.
  Escaffre O, Saito TB, Juelich TL, Ikegami T, Smith JK, Perez DD, Atkins C, Levine CB, Huante MB, Nusbaum RJ, Endsley JJ, Freiberg AN, Rockx B. J Virol. 2017 Jul 12;91(15). pii: e00275-17.
• Tick-Borne Encephalitis Virus in Ticks and Roe Deer, the Netherlands.
  Jahfari S, de Vries A, Rijks JM, Van Gucht S, Vennema H, Sprong H, Rockx B. Emerg Infect Dis. 2017 Jun;23(6):1028-1030.
• High Prevalence of Tula Hantavirus in Common Voles in The Netherlands.
  Maas M, de Vries A, van Roon A, Takumi K, van der Giessen J, Rockx B. Vector Borne Zoonotic Dis. 2017 Mar;17(3):200-205.
• Characterization of Nipah virus infection in a model of human airway epithelial cells cultured at an air-liquid interface.
  Escaffre O, Borisevich V, Vergara LA, Wen JW, Long D, Rockx B. J Gen Virol. 2016 May;97(5):1077-86.
  
  

For more publications visit this page.